Is the duration of adjuvant trastuzumab debate still clinically relevant?
Lancet
.
2019 Jun 29;393(10191):2565-2567.
doi: 10.1016/S0140-6736(19)30946-8.
Epub 2019 Jun 6.
Author
Sara A Hurvitz
1
Affiliation
1
David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA. Electronic address: shurvitz@mednet.ucla.edu.
PMID:
31178153
DOI:
10.1016/S0140-6736(19)30946-8
No abstract available
Publication types
Comment
MeSH terms
Breast Neoplasms*
Disease-Free Survival
Humans
Receptor, ErbB-2
Trastuzumab
Substances
Receptor, ErbB-2
Trastuzumab